Key result
Multimodal Remission Clinic strategy achieves proteinuria remission and stabilizes kidney function.
Why the study?
Despite renin-angiotensin system inhibition, most patients with chronic kidney disease progress to end-stage renal disease, highlighting the need for innovative therapies to halt or reverse progression.
Does a multimodal strategy including dual RAS inhibition and intensive risk factor management prevent progression to ESRD in patients with CKD and refractory proteinuria?
Does a multimodal strategy including dual RAS inhibition and intensive risk factor management prevent progression to ESRD in patients with CKD and refractory proteinuria?
A multimodal clinic approach utilizing dual RAS inhibition, intensive blood pressure control, statins, and lifestyle modifications may halt progression to ESRD in high-risk CKD patients with refractory proteinuria.
No takes yet. Share an insight, caveat, or question.
May support RAS inhibitor use for proteinuria reduction in nephropathies; leaves open optimal regimens in nondiabetic subgroups.
A 2011 study conducted a review in Chronic kidney disease with nephrotic-range proteinuria. Remission Clinic approach (multimodal strategy) was evaluated on Remission or regression of proteinuria and stabilization of kidney function. A multimodal Remission Clinic approach utilizing dual RAS inhibition, intensive blood pressure control, statins, and lifestyle changes achieved remission of proteinuria and stabilized kidney function.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: